-
Significant Increase In Deaths For Aranesp Users In Comparison To Patients Taking Placebo
Amgen-Sponsored Study Was Testing Aranesp In Cancer Patients Who Developed Anemia (Posted by Tom Lamb at DrugInjuryWatch.com) An April 17, 2007 Wall Street Journal (WSJ) article about the results of a new study concerning…
-
Vioxx Judge Wilson In Texas Might Rule For Merck On Preemption Issue And Dismiss Ledbetter Case
WSJ Reports That Judge Wilson’s Ruling In This One Vioxx Case Could Affect Other 1000 Texas Vioxx Cases (Posted by Tom Lamb at DrugInjuryWatch.com) Reporter Heather Won Tesoriero broke the news in an April…
-
Third California Vioxx Trial A No-Go; Plaintiff Berwick Drops Case Day Before Jury Selection Was To Start
Judge Victoria Chaney To Consider Status Of Upcoming California State Court Vioxx Trials At April 11, 2007 Hearing (Posted by Tom Lamb at DrugInjuryWatch.com) Plaintiff Lowell Berwick, who claimed his March 2004 heart attack…
-
FDA Orchestrates Voluntary Recall of Parkinson’s Disease Drug Permax
Action Follows News Of Studies Which Revealed Link To Serious Heart Valve Damage (Posted by Tom Lamb at DrugInjuryWatch.com) On March 29, 2007 the FDA announced that Permax as well as two generic pergolide…
-
Constipation Medication Zelnorm Linked To Apparent Increased Risk Of Heart Attacks And Strokes
Novartis Suspends Sales After FDA Determines That Risks Of Serious Side Effects Outweigh Benefits Of Zelnorm (Posted by Tom Lamb at DrugInjuryWatch.com) On March 30, 2007 the FDA announced that Novartis Pharmaceuticals Corporation had…
-
Heart Failure Drug Natrecor Fails Efficacy Part Of “Off-label” Use Study
Safety Profile Of Natrecor Continues To Be Subject Of Controversy And Debate (Posted by Tom Lamb at DrugInjuryWatch.com) The results of a large study for Johnson & Johnson’s heart failure drug Natrecor failed to…